bimekizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
monoclonal antibodies (humanized origin); interleukin and interleukin receptors	5478	1418205-77-2

Description:

Molecule	Description
Molfile Synonyms: bimekizumab bimzelx UCB4940 bimekizumab (genetical recombination)	Bimekizumab is a humanised IgG1/kappa monoclonal antibody that selectively binds with high affinity to IL-17A, IL-17F and IL-17AF cytokines, blocking their interaction with the IL-17RA/IL-17RC receptor complex. Elevated concentrations of IL-17A and IL-17F have been implicated in the pathogenesis of several immune-mediated inflammatory diseases including plaque psoriasis. Bimekizumab inhibits these proinflammatory cytokines, resulting in the normalization of skin inflammation and as a consequence improvement in clinical symptoms associated with psoriasis. From in vitro models, bimekizumab was shown to inhibit psoriasis-related gene expression and cytokine production to a greater extent than inhibition of IL-17A alone. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Molfile

Synonyms:

bimekizumab
bimzelx
UCB4940
bimekizumab (genetical recombination)

Bimekizumab is a humanised IgG1/kappa monoclonal antibody that selectively binds with high affinity to IL-17A, IL-17F and IL-17AF cytokines, blocking their interaction with the IL-17RA/IL-17RC receptor complex. Elevated concentrations of IL-17A and IL-17F have been implicated in the pathogenesis of several immune-mediated inflammatory diseases including plaque psoriasis. Bimekizumab inhibits these proinflammatory cytokines, resulting in the normalization of skin inflammation and as a consequence improvement in clinical symptoms associated with psoriasis. From in vitro models, bimekizumab was shown to inhibit psoriasis-related gene expression and cytokine production to a greater extent than inhibition of IL-17A alone.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
5.70	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Aug. 20, 2021	EMA	UCB Pharma S.A.
Jan. 20, 2022	PMDA	UCB JAPAN CO., LTD.

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L04AC21	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Interleukin inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Plaque psoriasis	indication	200965009
Pustular psoriasis	indication	200973000
Erythrodermic psoriasis	indication	200977004
Inflammatory bowel disease	contraindication	24526004	DOID:0050589
Upper respiratory tract infection	contraindication	54150009
Oral candidiasis	contraindication	79740000	DOID:14262
Active tuberculosis	contraindication	427099000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Interleukin-17A	Cytokine	Q16552	IL17_HUMAN	ANTIBODY BINDING	Kd	11.46	DRUG LABEL	DRUG LABEL
Interleukin-17F	Cytokine	Q96PD4	IL17F_HUMAN	ANTIBODY BINDING	Kd	10.55	DRUG LABEL	DRUG LABEL
Interleukin-17AF	Cytokine	Q16552 Q96PD4	IL17_HUMAN IL17F_HUMAN	ANTIBODY BINDING	Kd	10.59	DRUG LABEL	DRUG LABEL

External reference:

ID	Source
09495UIM6V	UNII
C4519734	UMLSCUI
CHEMBL4297700	ChEMBL_ID
DB12917	DRUGBANK_ID
D11550	KEGG_DRUG
9878	INN_ID
9411	IUPHAR_LIGAND_ID
018864	NDDF
C000625981	MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

None